Abstract
Gliomas are the most common tumors accounting for 49% of all primary brain tumors and ~2% of all new cases of cancer in the United States. Approximately, 18,000 new gliomas are diagnosed each year in the United States and >60% belong to the most malignant grade IV glioblastomas. Most of these tumors are untreatable, and patients survive as an average of <12 months, and 16,000 will die of this disease during this time despite 30 years of intensive efforts to find an effective chemotherapy.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Baldwin RM, Parolin DAE, Lorimer IAJ (2008) Regulation of glioblastoma cell invasion by PKC and rhob. Oncogene 27:3587–3595
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmedland AB, Dewhirst MW, Bigner DD, Rich JN (2006) Glioma stem cells promote radioresistance by preferential activation of DNA damage response. Nature 444:756–760
Beier D, Rohrl S, Pillai DR, Schwarz S, Kunz-Schughart LA, Leukel P, Proescholdt M, Brawanski A, Bogdahn U, Trampe-Kieslich A, Giebel B, Wischhusen J, Reifenberger G, Hau P, Beirer CP (2008) Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res 14:5706–5715
Carter AN, Cole CL, Playle AG, Ramsay EJ, Shervington AA (2009) GPR26: a marker for primary glioblastoma?. Mol Cell Probes 22:133–137
Dai C, Holland EC (2001) Glioma models. Biochem Biophys Acta 1551:M19–M27
de Goot JF, Yung WK (2008) Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas. Cancer J 14:279–285
Eramo A, Ricci-Vitiani L, Zeuner A, Pallini R, Lotti F, Sette G, Pilozzi E, Larocca LM, Peschle C, De Maria R (2006) Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ 13:1238–1241
Glas M, Koch H, Hirschman B, Jauch T, Steinbrecher A, Herrlinger U, Bagdahn U, Hau P (2007) Pegylated liposomal doxorubicin in recurrent malignant glioma: analysis of a case series. Oncology 72:302–307
Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, Otten P, VanMelle G, de Tribolet N, Stupp R (2004) Clinical trial substantiates the predictive value of 0-6-methylguanine-DNA methyl-transferase promoter methylation in glioblastoma patients treated with tomozolomide. Clin Cancer Res 10:1871–1874
Hegi B, Diserens AC, Gorila T, Hamou F, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2006) MGMT gene silencing and benefits from temozolomide in glioblastoma. N Engl J Med 352:997–2005
Kang M-K, Kang S-K (2007) Tumorigenesis of chemotherapeutic drug- resistant cancer stem- like cells in brain glioma. Stem Cells Develop 16:837–847
Lia A, Filka E, McGibbon B, Nghiemphu Pl, Graham C, Yong WH, Mischel P, Liau LM, Bergsneider M, Pope W, Selch M, Cloughesy T (2008) Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys 71:1372–1380
Maher EA, Furnari FB, Bachoo M, Rowitch DH, Louis DN, Cavenee WK, DePinho RA (2001) Malignant glioma: genetics and biology of a grave matter. Genes Develop 15:1311–1333
Marko NF, Toms SA, Barnett GH, Weil R (2008) Genomic expression patterns distinguish long-term glioblastoma survivors: a preliminary feasibility. Genomics 91:395–406
Mathieu V, De Neve N, Le Mercier M, Dewelle J, Gaussin J-F, Dehoux M, Kiss R, Lefranc F (2008) Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblatoma orthotopic xenograft model. Neoplasia 10:1383–1392
McLendon RE, Turner K, Perkinsen K, Rich J (2007) Second messenger systems in human gliomas. Arch Pathol Lab Med 131:1585–1590
Neyns B, Cordera S, Joosens E, Nader P (2008) Non-hodgkin’s lymphoma in patients with glioma-treated with temozolomide. J Clin Oncol:4518–4519
Nieder C, Wiedenmann N, Andratschke N, Molls M (2006) Current status of angiogenesis inhibitors combined with radiation therapy. Cancer Treat Rev 32:348–364
Ohgaki H, Kleihues P (2007) Genetic pathways to primary and secondary glioblastomas. Am J Pathol 170:1445–1453
Padros MD, Lamberton K, Yung WK, Jaeckle K, Robins HI, Mehta M, Fine HA, Wen PY, Cloughesy T, Chang S, Nicholas MK, Schiff D, Greenberg H, Junck H, Fink K, Kuhn J (2006) A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol 8:189–193
Sasai K, Nodagashira M, Nishihara H, Aoyanagi E, Wang L, Katoh M, Murata J, Ozaki Y, Ito T, Fujimoto S, Kaneko S, Nagashima K, Tamaka S (2008) Careful exclusion of non-neoplastic brain components is required for an appropriate evaluation of O6-methylguanine-DNA methyltransferase status in glioma: relationship between immunohistochemistry and methylation analysis. Am J Surg Pathol
Shono T, Yokoyama N, Uesaka T, Kuroda J, Takeya R, Yamasaki T, Amano T, Mizoguchi M, Suzuki SO, Niiro H, Miyamoto K, Akashi K, Iwaki T, Sumimoto H, Sasaki T (2008) Enhanced expression of NADPH oxidase NOX4 in human gliomas and its roles in cell proliferation and survival. Int J Cancer 123:787–792
Stupp R, Mason WP, van den Bent MJ, Weller M, Fischer B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross G, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Hayat, M. (2011). Introduction. In: Hayat, M. (eds) Tumors of the Central Nervous System, Volume 1. Tumors of the Central Nervous System, vol 1. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-0344-5_1
Download citation
DOI: https://doi.org/10.1007/978-94-007-0344-5_1
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-0343-8
Online ISBN: 978-94-007-0344-5
eBook Packages: MedicineMedicine (R0)